
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has demonstrated strong commercial execution, particularly with the recent easing of REMS requirements for its product FILSPARI, which is expected to enhance prescriber adoption rates. The company's pipeline candidate, sparsentan, continues to show accelerating sales and is on a favorable regulatory path in Japan, solidifying its potential as a foundational therapy for IgA nephropathy. Additionally, the cancellation of the AdCom alongside these regulatory advancements has positively influenced market sentiment, reflecting optimism regarding the company's future growth prospects.
Bears say
The negative outlook for Travere Therapeutics's stock is predominantly influenced by uncertainty surrounding the success of its clinical trials, particularly for its late-stage candidate, sparsentan, which focuses on rare kidney disorders. Compounding this risk are concerns regarding the company's ability to secure sufficient funding to advance its drug development, especially in light of recent FDA actions and shifting regulatory practices that have resulted in increased scrutiny and mixed sentiment among investors. Additionally, leadership changes within the company have further exacerbated the volatility and uncertainty in the biopharmaceutical landscape, potentially hindering future growth and investor confidence.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares